title: Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1.
abstract: BACKGROUND
  Management of pregnant women with human immunodeficiency virus (HIV) type 2 infection remains unclear because of its low prevalence and important differences from HIV-1.
  
  
  METHODS
  Pregnant women monoinfected with HIV-2 or HIV-1 and their infants enrolled in the prospective, national, multicenter French Perinatal Cohort between 1986 and 2007.
  
  
  RESULTS
  Overall, 2.6% (223/8660) of mothers were infected with HIV-2, and they accounted for 3.1% (367/ 11841) of the total births. Most were born in sub-Saharan Africa. A higher proportion of HIV-2-infected mothers than HIV-1-infected mothers had no symptoms, had received no antiretroviral therapy at conception (85.9% vs 66.7%), and had received no antiretroviral therapy during pregnancy (42.8% vs 19.9%), particularly highly active antiretroviral therapy (HAART) (79.7% vs 46.1%), and they had higher CD4 cell counts near delivery (median, 574 vs 452 cells/mm3; P < .01). If antiretroviral therapy was used, it was started at a later gestational age for HIV- 2-infected mothers (median, 28 vs 25 weeks; P < .01). HIV-2-infected mothers were more likely to deliver vaginally (67.9% vs 49.3%) and to breastfeed (3.6% vs 0.6%; P < .01), and their infants less frequently received postexposure prophylaxis. In the period 2000-2007, the proportion with viral load <100 copies/mL at delivery was 90.5% of HIV-2-infected mothers, compared with 76.2% of HIV-1-infected mothers (P=.1). There were 2 cases of transmission: 1 case in 1993 occurred following maternal primary infection, and the other case occurred postnatally in 2002 and involved a mother with severe immune deficiency. The mother-to-child transmission rate for HIV-2 was 0.6% (95% confidence interval, 0.07%-2.2%).
  
  
  CONCLUSIONS
  Care for HIV-2-infected pregnant women rests on expert opinion. The mother-to-child transmission residual rate (0.07%-2.2%) argues for systematic treatment: protease inhibitor-based HAART for women requiring antiretrov
authors.affiliation: Virology Laboratory, Hospital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Burgard
authors.forename: C
authors.initials: C
authors.lastname: Jasseron
authors.forename: S
authors.initials: S
authors.lastname: Matheron
authors.forename: F
authors.initials: F
authors.lastname: Damond
authors.forename: K
authors.initials: K
authors.lastname: Hamrene
authors.forename: S
authors.initials: S
authors.lastname: Blanche
authors.forename: A
authors.initials: A
authors.lastname: Faye
authors.forename: C
authors.initials: C
authors.lastname: Rouzioux
authors.forename: J
authors.initials: J
authors.lastname: Warszawski
authors.forename: L
authors.initials: L
authors.lastname: Mandelbro
mesh_terms: D000328:Adult; D015331:Cohort Studies; D005260:Female; D005602:France; D015658:HIV Infections / Q000635:transmission* / Q000821:virology*; D015498:HIV-2 / Q000302:isolation & purification*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000821:virology*